KaloBios Gets $12M Genzyme, Baxter

Xconomy Boston — 

KaloBios Pharmaceuticals, a South San Francisco-based biotech company, said today it has raised $12 million in the second closing of a $32 million Series D round of venture financing. Baxter International, Genzyme Ventures, and Mitsubishi UFJ Capital were among the investors in the round. The company is developing a human antibody fragment to fight bacterial infections in cystic fibrosis patients, as well as another candidate for autoimmune diseases like asthma and rheumatoid arthritis.